Firm News
Wiggin and Dana advises BioArctic AB in Option, Collaboration and License Agreement with Novartis Pharma AG
Wiggin and Dana represented BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) in connection with its option, collaboration, and license agreement with Novartis Pharma AG, combining BioArcticโs proprietary BrainTransporterโข technology with a Novartis proprietary antibody directed to an undisclosed target in neurodegeneration. Under the agreement, BioArctic will receive a $30 million up-front payment, and if Novartis exercises their option, BioArctic will be eligible to receive additional payments of up to $772 million plus tiered mid-single digit royalties.
The Wiggin deal team consisted of Toby Bannon, Patti Melick, and David Devich.
To learn more and read the official press release, please click here.